Evidence map›Paper›PMID 41182890›Full record

ArticleCancer science2026

Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids With

Mitsuyoshi Yoshimoto, Shun-Ichi Wada, Yukie Yoshii, Sayaka Hanadate, Anri Inaki, Hirofumi Fujii

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mitsuyoshi YoshimotoDivision of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-2083-9148
Shun-Ichi WadaDepartment of Bioorganic Chemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yukie YoshiiLinqMed Inc., Tokyo, Japan.
Sayaka HanadateLinqMed Inc., Tokyo, Japan.
Anri InakiDivision of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Hirofumi FujiiDivision of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Funding

Japan Agency for Medical Research and Development, P-PROMOTE 24ama221601
6 · The paper itself

Abstract

Improved peptide pharmacokinetics are needed to enhance the therapeutic effects of peptide-based radionuclide therapy. Conjugation of albumin binders, such as fatty acids, to tumor-targeting peptides slows blood clearance, resulting in higher tumor uptake. In this study, we synthesized PD-conjugated monomeric and dimeric RGD peptides, PD-K-(

Indexed as

Fatty AcidsLutetiumOligopeptidesRadioisotopesRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CTissue Distributionarginyl-glycyl-aspartic acidFatty AcidsLutetiumLutetium-177OligopeptidesRadioisotopesRadiopharmaceuticalsalbumin bindingintegrinspentadecanoic acidradionuclide therapyRGD peptide

Identifiers

PMID41182890
PMCPMC12775587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.